Skip to main content

Table 3 Estimation of potential outcome means between second − line drugs: Treatment effect model with inverse probability weighting and regression adjustment

From: Effects of second-line antihyperglycemic drugs on the risk of chronic kidney disease: applying a target trial approach to a hospital-based cohort of Thai patients with type 2 diabetes

Treatment

POM

Lower limit

Upper limit

ITT

   

SGLT2i

0.037

0.012

0.063

DPP4i

0.133

0.122

0.143

TZD

0.175

0.157

0.193

SU

0.179

0.173

0.185

PPA

   

SGLT2i

0.024

0.002

0.046

DPP4i

0.146

0.132

0.161

TZD

0.194

0.172

0.216

SU

0.201

0.193

0.208

Modified ITT

   

SGLT2i

0.037

0.012

0.063

DPP4i

0.133

0.122

0.143

TZD

0.175

0.157

0.193

SU

0.179

0.173

0.185

  1. DPP4i: Dipeptidyl peptidase-4 inhibitors; ITT: Intention-to-reat; POM: Potential outcome mean; PPA: Per-protocol analysis; SGLT2i: Sodium-glucose cotransporter-2 inhibitors; SU: Sulfonylureas; TZD: Thiazolidinediones
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840